SHAREHOLDER Inform: WeissLaw LLP Investigates Sunesis Pharmaceuticals, Inc.

NEW YORK, Nov. 30, 2020 /PRNewswire/ — WeissLaw LLP is investigating achievable breaches of fiduciary duty and other violations of legislation by the board of administrators of Sunesis Prescribed drugs, Inc. (“Sunesis ” or the “Enterprise”) (NASDAQ: SNSS) in relationship with the Firm’s proposed merger with privately-held Viracta Therapeutics, Inc. (“Viracta”).  Under the phrases of the merger settlement, Sunesis and Viracta will merge, resulting in current Viracta stockholders owning 86{0fd7e6f75ade3d5ae67778d77dd996bcc8aca117c4e234285c3d1a0079535f7c} of the article-shut enterprise and leaving only 14{0fd7e6f75ade3d5ae67778d77dd996bcc8aca117c4e234285c3d1a0079535f7c} of the surviving entity to latest Sunesis stockholders.  The mixed business will run below the identify Viracta Therapeutics, Inc. and will continue to trade on the NASDAQ below the new ticker symbol “VIRX.” 

If you possess Sunesis shares and wish to discuss this investigation or have any concerns about this discover or your legal rights or interests, check out our web site:

Or make sure you get in touch with:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Flooring
New York, NY  10036
(212) 682-3025
(888) 593-4771

WeissLaw is investigating (i) no matter if Sunesis’ board acted in the finest interest of Sunesis’ public stockholders in agreeing to the proposed transaction, (ii) irrespective of whether the board was entirely informed as to the worth of privately-held Viracta, (iii) no matter whether the deal’s equity split is truthful to Sunesis’ stockholders, and (iv) whether or not all data regarding the sales method undertaken by the board and money analyses supporting the transaction will be thoroughly and reasonably disclosed to Sunesis’ public stockholders. 

WeissLaw LLP has litigated hundreds of stockholder class and spinoff actions for violations of company and fiduciary duties.  We have recovered around a billion bucks for defrauded customers and received essential corporate governance reduction in numerous of these instances.  If you have info or would like lawful suggestions about possible corporate wrongdoing (together with insider investing, waste of company property, accounting fraud, or materially deceptive data), consumer fraud (such as bogus promotion, defective goods, or other misleading enterprise methods), or anti-have confidence in violations, remember to email us at

Cision See authentic written content to obtain multimedia:

Supply WeissLaw LLP